S1181 Gastrointestinal and Hepatic Manifestations of COVID-19: A Case Series of 711 Patients
| Autor: | Thu Vu, Fuad I Abaleka, Maria Kamel, Bisrat Nigusse, Mina Daniel, Sher N. Baig, George Abdelsayed, Stephanie Herrea |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | American Journal of Gastroenterology. 115:S591-S591 |
| ISSN: | 1572-0241 0002-9270 |
| DOI: | 10.14309/01.ajg.0000706772.65555.fd |
| Popis: | INTRODUCTION: Gastrointestinal (GI) symptoms and liver function test (LFT) abnormalities are increasingly being reported in patients with COVID-19 but there is no reliable data on the real magnitude of GI tract involvement We present the results of our study of 711 patients for GI and liver manifestations of COVID-19 METHODS: We performed a retrospective chart review of the 711 adult patients who visited the Richmond University Medical Center and/or its ambulatory centers in New York City up until May 13, 2020, and tested positive for COVID-19 We analyzed the reported incidence of dysgeusia, anorexia, nausea, vomiting, diarrhea, abdominal pain, and GI bleeding as well as LFT abnormalities In case of deranged LFTs, we looked for preexisting liver disease, alcohol abuse, and anti-retroviral medication use RESULTS: A total of 711 patients were studied using inpatient charts, and laboratory data to identify abnormal findings The mean age of patients was 60 5 years with slight male predominance (n = 395 vs 316) 27 1% (n = 193) reported GI symptom and an additional 56 9% (n = 405) had at least one liver enzyme abnormality Diarrhea was the most common with a frequency of 17 3% (n = 86), nausea 16 2% (n = 80), anorexia/vomiting 13 7% (n = 68), and abdominal pain 5 6% (n = 28) The least reported symptoms were dysgeusia 3 2% (n = 16) and GI bleeding 2 2% (n = 11) Lipase level was elevated in 27 8% patients (n = 138) Among LFTs, AST alone was elevated in 16 6% (n = 118), ALT alone in 15 0% (n = 6), both AST/ALT 15 7% (n = 112), alkaline phosphatase 23% (n = 164), and bilirubin 10% (n = 71) Potential confounders were preexisting liver disease (n = 8), patients taking HIV medications (n = 9) and alcohol abuse However, the enzyme levels in these patients were elevated above their baseline PT/ INR was elevated in 13 4% (n = 95) of patients while only 27 of them were on oral anticoagulant 88 6% (n = 630) of patients were admitted with respiratory failure, and 28 5% (n = 203) died CONCLUSION: GI symptoms were experienced by 27% and hepatic dysfunction was at 57% in this study of 711 COVID-19 patients This reflects a fairly high burden of GI involvement As the covid- 19 pandemic continues its rampage, our understanding of its GI and hepatobiliary aspects is growing This will improve our diagnostic, therapeutic, and preventive armamentarium Other implications for gastroenterlogists include prolonged viral shedding in stools, potential for fecal-oral transmission and risk of exposure during endocsopy (Table Presented) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|